Strategic partnership enables physicians to conduct clinical research and offer new clinical therapies to their patients
August 17 2017 - 4:01PM
Allscripts (NASDAQ:MDRX) has partnered with Elligo Health
Research to assist clinicians to conduct clinical trial studies in
their own clinics. Through the Allscripts / Elligo partnership,
clinical trials managed by Clinical Research Organizations (CROs)
will be available, bringing new treatments to patients across major
therapeutic areas.
The combined offering enables physicians to
directly participate as study investigators in selected CRO
clinical trials, and delivers the physicians’ patients the benefit
of more direct comprehensive care. Additionally, physicians
will be able to generate research revenue and cover investigator
fees associated with trial procedures.
The Allscripts eParticipateSM service will be
available to all Allscripts clients using the EHR platforms –
Allscripts Professional EHR™, Allscripts TouchWorks® EHR and
Allscripts Sunrise™.
CROs continue to increase investments to support
bringing new clinical therapies to market, with more than $17
billion in payments to study investigators. eParticipate expands
the reach of clinical trials investments by enabling Allscripts
research-capable sites to become study investigators through
Elligo’s infrastructure and services. Allscripts physicians will
have access to clinical trials across several therapeutic areas,
including Gastroenterology, Neurology, Pain, Urology, Pulmonology,
Oncology and Women’s Health, some of the key areas of focus for
CROs.
“By bringing clinical trials directly to their
patients, physicians can remain focused on the direct care of
patients while offering them new therapies,” said Allscripts Senior
Vice President and General Manager of Payer and Life Sciences Jay
Bhattacharyya. “Physicians will be able to participate in the
benefits of clinical research without investing in expensive
infrastructure.”
“Through our partnership with Allscripts, health
care providers can identify patients for potential clinical
research opportunities directly through their EHR,” said President
of Elligo Health Research, Chad Moore. “Not only will patients gain
access to treatments they might not have had otherwise, they will
also participate from the comfort of their own physician’s
office.”
About AllscriptsAllscripts
(NASDAQ:MDRX) is a leader in healthcare information technology
solutions that advance clinical, financial and operational results.
Our innovative solutions connect people, places and data across an
Open, Connected Community of Health™. Connectivity empowers
caregivers and consumers to make better decisions, delivering
better care for healthier populations. To learn more, visit
www.allscripts.com, Twitter,
YouTube and It Takes A Community: The
Allscripts Blog.
About Elligo Health
ResearchElligo Health Research offers the only platform
that brings clinical research to the clinic, accelerating the
development of new pharmaceutical, biotechnology and medical device
products and therapies. Elligo Goes Direct™ with an approach that
uses electronic health records and other health data to identify
real-world physicians and patients for participation in clinical
studies. It is our mission to support health care providers by
providing personnel, procedures, technology and infrastructure for
clinical research, enabling patients to participate in research
while remaining under the care of their own trusted physician.
Learn more at elligodirect.com.
© 2017 Allscripts Healthcare, LLC and/or its
affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other
Allscripts marks are trademarks of Allscripts Healthcare, LLC
and/or its affiliates. All other products are trademarks of their
respective holders, all rights reserved. Reference to these
products is not intended to imply affiliation with or sponsorship
of Allscripts Healthcare, LLC and/or its affiliates.
For more information contact:
Allscripts Investors:
Seth Frank
312-506-1213
seth.frank@allscripts.com
Allscripts Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com
Elligo Media:
Lea Studer
308-237-5567
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Sep 2023 to Sep 2024